SCHEMBL3533346

SCHEMBL3533346

C[C@@H]1CN(c2ccc3nc(-c4n[nH]c5ccccc45)[nH]c3c2)C[C@H](C)O1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 14/20 0.70
FLT1 P17948 11/20 0.70
ABL1 P00519 4/20 0.62
ITK Q08881 3/20 0.56
KDR P35968 4/20 0.55
PDPK1 O15530 3/20 0.55
FGFR3 P22607 2/20 0.55
SYK P43405 2/20 0.55
PLK4 O00444 1/20 0.55
CHEK1 O14757 1/20 0.55
AURKA O14965 1/20 0.55
CHUK O15111 1/20 0.55
JAK2 O60674 1/20 0.55
ROCK2 O75116 1/20 0.55
MAP4K4 O95819 1/20 0.55
PAK4 O96013 1/20 0.55
CHEK2 O96017 1/20 0.55
NTRK1 P04629 1/20 0.55
PRKCG P05129 1/20 0.55
INSR P06213 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6592039 1.00 FGFR1 (0.70) FGFR1FLT1ABL1ITKKDR
SCHEMBL3535793 0.81 FGFR1 (0.81) FGFR1FLT1ABL1ITKKDR
SCHEMBL3543211 0.81 FGFR1 (0.80) FGFR1FLT1ABL1ITKKDR
SCHEMBL14906539 0.78 FGFR1 (0.90) FGFR1FLT1ABL1KDRFGFR3
SCHEMBL3537562 0.77 FGFR1 (0.61) FGFR1FLT1ABL1KDR
SCHEMBL3535377 0.77 FGFR1 (0.77) FGFR1FLT1ABL1KDR
SCHEMBL3533364 0.75 FGFR1 (0.85) FGFR1FLT1ABL1ITKPDPK1
SCHEMBL3532400 0.75 FGFR1 (0.54) FGFR1FLT1ABL1ITKKDR
SCHEMBL14906746 0.73 CBFB (0.62) FGFR1KDRFGFR3FGFR2
SCHEMBL31172319 0.73 FGFR1 (0.61) FGFR1FLT1KDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed
EP-1401831-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2004-03-31 EP disclosed
US-20030207883-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2003-11-06 US disclosed
WO-2003004488-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885ABL1 1/4885
US-20030207883-A1 Indazole benzimidazole compounds SLCO1B3, SLCO1B1, SLCO4C1 FGFR1 2175/4885FLT1 3562/4885ABL1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.